← Russell 3000 cross-section

DNTH Dianthus Therapeutics, Inc. /DE/

Trailing twelve months to 2025-12-31 · as filed 2026-03-09, not restated
Healthcare

Scale

Market cap
$6.2bn
Revenue TTM
$2m
Net income TTM
$-162m
Free cash flow
Composite score
Sector rank
#952

Valuation

P / E
EV / EBITDA
EV / sales
2,836.6
FCF yield
Earnings yield vs 10-yr
-7.36pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-7,973.3%
EBITDA margin
-8,733.9%
ROE
-32.9%
ROIC
-199.7%
Revenue growth

Insider activity, last 90 days

Net open-market
$-29.62m
Buyers
0
Sellers
6

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

No sales were made under the ATM offering program during the three and six months ended June 30, 2025. No sales were made under the ATM offering program during the six months ended June 30, 2025. The consideration under the Tenacia License Agreement, which replaced the consideration of the Zenas License Agreement, related to the first antibody sequence includes the following payments by Tenacia to the Company: (i) a $ 2.5 million upfront payment, which was paid to the Company in October 2024 upon execution of the Tenacia License Agreement; (ii) reimbursement of a portion 18 of certain clinical costs; (iii) development milestones totaling up to $ 15.0 million; and (iv) royalties on net sales …Dianthus Therapeutics, Inc. /DE/, 10-Q, period ended 2026-06-30, filed 2026-08-04

Read the full passage →